Panzilan (Pantoprazole)

Pantoprazole, the active ingredient in Panzilan, is a proton pump inhibitor presented as an oral tablet for systemic use. It reduces gastric acid secretion and is employed to manage acid‑related gastrointestinal disorders in adult patients.

GNH USA supplies Panzilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor used to treat conditions associated with excessive gastric acid production.

- Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal healing and reduces recurrence of lesions. - Zollinger‑Ellison syndrome: controls hypersecretion of gastric acid in this rare endocrine disorder.

Pantoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea with abdominal cramps. - Low serum magnesium: muscle weakness, irregular heartbeat. - Liver enzyme elevation: asymptomatic increase in transaminases. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function assessment: adjust use in patients with severe impairment. - Magnesium monitoring: periodic checks during prolonged treatment. - Hepatic impairment: use with caution in moderate to severe liver disease. - Rebound acid hypersecretion: avoid abrupt discontinuation after long‑term use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and therapeutic effect. - Atazanavir: markedly decreased plasma concentrations. - Clopidogrel: diminished activation leading to reduced antiplatelet activity.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Digoxin: possible rise in serum levels; observe for toxicity signs.